Benzinga | Nov 9, 2020 07:04AM EST

Intercept Pharmaceuticals Q3 EPS $(2.01) Misses $(1.93) Estimate, Sales $79.50M Beat $78.63M Estimate

Intercept Pharmaceuticals (NASDAQ:ICPT) reported quarterly losses of $(2.01) per share which missed the analyst consensus estimate of $(1.93) by 4.15 percent. This is a 22.39 percent increase over losses of $(2.59) per share from the same period last year. The company reported quarterly sales of $79.50 million which beat the analyst consensus estimate of $78.63 million by 1.11 percent. This is a 28.33 percent increase over sales of $61.95 million the same period last year.